Spero Therapeutics (NASDAQ:SPRO) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Spero Therapeutics (NASDAQ:SPRO) from a strong-buy rating to a hold rating in a research note released on Saturday morning.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Spero Therapeutics in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Spero Therapeutics Trading Up 1.1%

NASDAQ:SPRO opened at $2.79 on Friday. The company’s 50-day moving average price is $2.56 and its 200-day moving average price is $2.43. The company has a market cap of $161.54 million, a P/E ratio of 11.63 and a beta of 1.43. Spero Therapeutics has a twelve month low of $0.63 and a twelve month high of $3.22.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.26 million. Spero Therapeutics had a net margin of 24.90% and a return on equity of 35.58%.

Insider Activity

In other news, insider Esther Rajavelu sold 25,240 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $2.51, for a total value of $63,352.40. Following the sale, the insider directly owned 986,851 shares of the company’s stock, valued at approximately $2,476,996.01. The trade was a 2.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. GSK plc purchased a new stake in shares of Spero Therapeutics in the 4th quarter valued at approximately $21,414,000. Vanguard Group Inc. raised its stake in shares of Spero Therapeutics by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,989,855 shares of the company’s stock valued at $3,741,000 after acquiring an additional 39,474 shares during the period. State Street Corp raised its stake in shares of Spero Therapeutics by 10.1% in the 4th quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after acquiring an additional 19,200 shares during the period. Ionic Capital Management LLC raised its stake in shares of Spero Therapeutics by 39.2% in the 3rd quarter. Ionic Capital Management LLC now owns 208,725 shares of the company’s stock valued at $392,000 after acquiring an additional 58,725 shares during the period. Finally, Intrepid Family Office LLC raised its stake in shares of Spero Therapeutics by 50.0% in the 4th quarter. Intrepid Family Office LLC now owns 165,000 shares of the company’s stock valued at $384,000 after acquiring an additional 55,000 shares during the period. 25.60% of the stock is owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical?stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug?resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram?negative pathogens.